RTEL1 Gene Mutation Analysis
The RTEL1 gene is located on the long (q) arm of chromosome 20 at position 13.33. This gene encodes for ‘regulator of telomere elongation helixcase 1’ (RTEL1) an essential iron-sulfur (FeS)-containing DNA helicase that is crucial for telomere maintenance and DNA repair. This helicase has also been implicated as an anti-recombinase in that it disrupts D-loop formation during homologous recombination and is essential for the disassembly of T-loops at the end of telomeres during DNA replication. Mutations in this gene have been associated with dyskeratosis congenita, and Hoyerall-Hreidarsson syndrome.
Dyskeratosis congenita (DC) is a disorder caused by over 13 different mutations including mutations in the RTEL1 gene. DC caused by mutatioins in RTEL1 may be inherited in either an autosomal dominant or autosomal recessive manner. The disorder is characterized by the classic triad of: lacy hyperpigmentation of the upper chest and neck, oral leukoplakia, and dystrophic nails. Individuals with dyskeratosis congenita have an increased risk of developing pulmonary fibrosis as well as several types of cancer. Most affected individuals also develop bone marrow failure by age 40, resulting in anemia, leukopenia and thrombocytopenia. DC caused by RTEL1 mutations is more common in individuals of Ashkenazi Jewish ancestry due to a founder mutation (c.3791G>A; p.Arg1264His).
Hoyeraal-Hreidarsson syndrome (HHS) is a rare, multisystem, disorder characterized by excessively short telomeres and is considered a severe form of dyskeratosis congenita. HHS is typically caused by mutations in the DKC1 gene and is inherited in an X-linked recessive manner. However, HHS may also be caused by autosomal recessives mutations in ACD, TERT, PARN and RTEL1. HHS mainly affects males and the disorder presents in early childhood with cerebellar hypoplasia, immunodeficiency, progressive bone marrow failure, and intrauterine growth retardation.
- For the confirmation of a clinical diagnosis of RTEL1-associated dyskeratosis congenital and Hoyeraal-Hreidarsson syndrome (HHS)
- For the carrier testing of family members of the affected patient
- For the prenatal diagnosis in at-risk pregnancies
- Identifying variants within genes known to be associated with increased risk for disease features allowing for predictive testing of at-risk family members
- For appropriate management and surveillance for disease features based on the gene involved
Positive: Mutation or pathogenic variant in RTEL1 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative: No mutation or pathogenic variant in RTEL1 gene.
Negative for mutation or pathogenic variant in RTEL1 gene
Whole blood (EDTA), Cultured cells, Skin biopsy.
Stability (blood)
Ambient: 3-5 days
Refrigerated: 7-14 days
- Am J Respir Crit Care Med. 2015;191: 646-55. [PMID: 25607374]
- Trends Cell Biol. 2014;24: 416-25. [PMID: 24582487]
- Hum Genet. 2013;132: 473-80. [PMID: 23329068]
- Expert Rev Hematol. 2013;6: 327-37. [PMID: 23782086]
- PLoS Genet. 2013;9: e1003695. [PMID: 24009516]
- Proc Natl Acad Sci U S A. 2013;110: E3408-16. [PMID: 23959892]
- Hum Mol Genet. 2013;22: 3239-49. [PMID: 23591994]
- Genetics Home Reference. Available: https://ghr.nlm.nih.gov/gene/RTEL1#